195 related articles for article (PubMed ID: 30181190)
1. Real-world health services utilisation and outcomes after
Dossa F; Cusimano MC; Sutradhar R; Metcalfe K; Little T; Lerner-Ellis J; Eisen A; Meschino WS; Baxter NN
BMJ Open; 2018 Sep; 8(9):e025317. PubMed ID: 30181190
[TBL] [Abstract][Full Text] [Related]
2. Building the What Comes Next Cohort for
Dossa F; Metcalfe K; Sutradhar R; Little T; Eisen A; Chun K; Meschino WS; Velsher L; Ellis JL; Baxter NN
CMAJ Open; 2021; 9(3):E874-E885. PubMed ID: 34870614
[TBL] [Abstract][Full Text] [Related]
3. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
4. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
5. Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
Collins IM; Milne RL; Weideman PC; McLachlan SA; Friedlander ML; ; Hopper JL; Phillips KA
Med J Aust; 2013 Nov; 199(10):680-3. PubMed ID: 24237098
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers.
Larouche G; Chiquette J; Plante M; Pelletier S; Simard J; Dorval M
Can Assoc Radiol J; 2016 Nov; 67(4):308-312. PubMed ID: 27318890
[TBL] [Abstract][Full Text] [Related]
7. Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study.
Metcalfe KA; Fan I; McLaughlin J; Risch HA; Rosen B; Murphy J; Bradley L; Armel S; Sun P; Narod SA
Gynecol Oncol; 2009 Jan; 112(1):68-72. PubMed ID: 19019415
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
9. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
10. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
11. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
[TBL] [Abstract][Full Text] [Related]
12. Women's experiences of undergoing BRCA1 and BRCA2 testing: organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Münster.
Nippert I; Schlegelberger B;
Community Genet; 2003; 6(4):249-58. PubMed ID: 15331871
[TBL] [Abstract][Full Text] [Related]
13. Genetic testing for BRCA1 and BRCA2 in the Province of Ontario.
Finch A; Wang M; Fine A; Atri L; Khalouei S; Pupavac M; Rosen B; Eisen A; Elser C; Charames G; Metcalfe K; Chang MC; Narod SA; Lerner-Ellis J
Clin Genet; 2016 Mar; 89(3):304-11. PubMed ID: 26219728
[TBL] [Abstract][Full Text] [Related]
14. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
16. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
[TBL] [Abstract][Full Text] [Related]
17. Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies.
Evans DG; Harkness E; Lalloo F; Howell A
J Med Genet; 2014 Sep; 51(9):573-80. PubMed ID: 25053764
[TBL] [Abstract][Full Text] [Related]
18. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.
Schwartz MD; Kaufman E; Peshkin BN; Isaacs C; Hughes C; DeMarco T; Finch C; Lerman C
J Clin Oncol; 2003 Nov; 21(21):4034-41. PubMed ID: 14581427
[TBL] [Abstract][Full Text] [Related]
19. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
